A Phase Two Study of Two Doses of Leronlimab (Pro 140) in Combination with Trifluridine + Tipiracil (TAS-102) + Bevacizumab in Participants with CCR5+, Microsatellite Stable (MSS), Relapsed Refractory Metastatic Colorectal Cancer (mCRC)

16086CD-O-101-NCT06699836OpenA Phase Two Study of Two Doses of Leronlimab (Pro 140) in Combination with Trifluridine + Tipiracil (TAS-102) + Bevacizumab in Participants with CCR5+, Microsatellite Stable (MSS), Relapsed Refractory Metastatic Colorectal Cancer (mCRC)CD-O-101NCT06699836IndustrialAdultTreatmentIIOtherNoel, MarcusGeorgetown University Medical Center : Princess Jones; Lombardi Comprehensive Cancer Center : Princess Jones; Medstar Washington Hospital CenterGastrointestinalOncology GroupLombardi Comprehensive Cancer Center (LCCC); Oncology PFS14509Princess JonesPrincess Jonespaj24@georgetown.edu2026.1.0 Build 16 <a href="https://advarra.com" target="_blank">© 2026 Advarra, Inc.</a>